We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cooper Companies Strong on Portfolio Expansion Plans
Read MoreHide Full Article
The Cooper Companies Inc. (COO - Free Report) is firing on all cylinders, buoyed by its expanding product portfolio and consistent earnings results. The momentum is boosting its share price, which is up 32.2% year-to-date as compared to the S&P 500’s return of 2.9%.
Cooper Companies through its operating companies – CooperVision (CVI) and CooperSurgical (CSI) – offer a wide range of contact lenses as well as medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians.
Cooper Companies’ policy of launching new products and updating the existing ones has been a key catalyst for years. The expanding product portfolio helps the company address user preferences, which are shifting from low-feature commodity lenses to more expensive single-use and specialty lenses, such as lenses with aspherical optical properties or higher oxygen permeable lenses (silicone hydrogels).
New Contact Lens
The growing usage of digital devices has created a new group of users who frequently complain of discomfort arising from prolonged usage of smartphones, tablets, laptops, in-car displays and other devices.
Despite the high usage, 90% of people do not feel that it is necessary to communicate the digital usage data with their eye care practitioners. The lack of awareness has been primarily blamed as the major reason behind tiredness, dryness and redness of eyes.
To address this condition, Cooper Companies recently launched Biofinity Energys contact lenses, which features Digital Zone Optics and Aquaform technologies.
According to Cooper Companies, “CooperVision Biofinity Energys contact lenses are designed for all-day wear, helping people’s eyes better adapt so they can seamlessly and continuously shift focus between digital devices and offline activities. After one week of wear, eight out of ten digital device users agreed that Biofinity Energys lenses made their eyes feel less tired.”
As the adoption rate of digital devices continues to rise, we believe that demand for Biofinity Energys will ramp up in the near future. The company has started rolling out the product in the U.S. on a phased manner beginning July. It is expected to enter the European markets later this year.
Growth Prospects
Apart from the CooperVision business, the company is also expected to benefit from the expanding CSI product portfolio. Management believes that CSI’s long-term growth will be driven by the fertility segment (a significant part of the women’s healthcare market), where Cooper Companies has gained a strong foothold driven by acquisitions (Reprogenetics, Genesis and Recombine).
Moreover, these acquisitions have provided Cooper Companies with a competitive edge in the women healthcare market. Boston Scientific (BSX - Free Report) and Johnson & Johnson (JNJ - Free Report) are two prominent players in this market.
A Peer
BioTelemetry (BEAT - Free Report) is a top-performing stock in the broader medical sector.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cooper Companies Strong on Portfolio Expansion Plans
The Cooper Companies Inc. (COO - Free Report) is firing on all cylinders, buoyed by its expanding product portfolio and consistent earnings results. The momentum is boosting its share price, which is up 32.2% year-to-date as compared to the S&P 500’s return of 2.9%.
Cooper Companies through its operating companies – CooperVision (CVI) and CooperSurgical (CSI) – offer a wide range of contact lenses as well as medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians.
Cooper Companies’ policy of launching new products and updating the existing ones has been a key catalyst for years. The expanding product portfolio helps the company address user preferences, which are shifting from low-feature commodity lenses to more expensive single-use and specialty lenses, such as lenses with aspherical optical properties or higher oxygen permeable lenses (silicone hydrogels).
New Contact Lens
The growing usage of digital devices has created a new group of users who frequently complain of discomfort arising from prolonged usage of smartphones, tablets, laptops, in-car displays and other devices.
COOPER COS Price and Consensus
COOPER COS Price and Consensus | COOPER COS Quote
Despite the high usage, 90% of people do not feel that it is necessary to communicate the digital usage data with their eye care practitioners. The lack of awareness has been primarily blamed as the major reason behind tiredness, dryness and redness of eyes.
To address this condition, Cooper Companies recently launched Biofinity Energys contact lenses, which features Digital Zone Optics and Aquaform technologies.
According to Cooper Companies, “CooperVision Biofinity Energys contact lenses are designed for all-day wear, helping people’s eyes better adapt so they can seamlessly and continuously shift focus between digital devices and offline activities. After one week of wear, eight out of ten digital device users agreed that Biofinity Energys lenses made their eyes feel less tired.”
As the adoption rate of digital devices continues to rise, we believe that demand for Biofinity Energys will ramp up in the near future. The company has started rolling out the product in the U.S. on a phased manner beginning July. It is expected to enter the European markets later this year.
Growth Prospects
Apart from the CooperVision business, the company is also expected to benefit from the expanding CSI product portfolio. Management believes that CSI’s long-term growth will be driven by the fertility segment (a significant part of the women’s healthcare market), where Cooper Companies has gained a strong foothold driven by acquisitions (Reprogenetics, Genesis and Recombine).
Moreover, these acquisitions have provided Cooper Companies with a competitive edge in the women healthcare market. Boston Scientific (BSX - Free Report) and Johnson & Johnson (JNJ - Free Report) are two prominent players in this market.
A Peer
BioTelemetry (BEAT - Free Report) is a top-performing stock in the broader medical sector.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>